DeepMed Research

Valneva Austria GmbH

🇦🇹Austria

Country: 🇦🇹Austria

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.valneva.at

Clinical Trials

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

Phase 3

Completed

Conditions: Japanese Encephalitis

Interventions: Procedure: Blood draw
Biological: IC51 has given in the parent study IC51-322

First Posted Date: 2010-11-23

Last Posted Date: 2020-03-18

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 23

Registration Number: NCT01246479

This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

Phase 4

Completed

Conditions: Japanese Encephalitis

Interventions: Biological: IXIARO®

First Posted Date: 2010-07-08

Last Posted Date: 2012-03-23

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 200

Registration Number: NCT01158599

Locations: 🇩🇪
Berliner Centrum Reise- und Tropenmedizin, Berlin, Germany
🇦🇹
Medical University of Vienna - Klinische Pharmakologie, Vienna, Austria
🇦🇹
Institut für Spezifische Prophylaxe und Tropenmedizin, Vienna, Austria

and more 2 locations

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Phase 3

Completed

Conditions: Encephalitis

Interventions: Biological: IC51

First Posted Date: 2010-01-13

Last Posted Date: 2020-06-30

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 100

Registration Number: NCT01047839

Locations: 🇩🇪
Berliner Zentrum für Reise- und Tropenmedizin, Berlin, Germany
🇺🇸
Tampa Clinical Research Inc., Tampa, Florida, United States
🇺🇸
Passport Health, Baltimore, Maryland, United States

and more 7 locations

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Phase 3

Completed

Conditions: Encephalitis

Interventions: Biological: IC51 Japanese Encephalitis
Biological: Havrix®720
Biological: Prevnar

First Posted Date: 2009-12-31

Last Posted Date: 2021-07-27

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 1869

Registration Number: NCT01041573

Locations: 🇵🇭
Research Institute for Tropical Medicine, Muntinlupa, Filinvest Corporate City, Philippines
🇵🇭
Department of Pediatrics, UP-Philippine General Hospital, Manila, Philippines

Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients

Phase 2

Completed

Conditions: Pneumonia, Ventilator-Associated

Interventions: Biological: IC43
Drug: Placebo

First Posted Date: 2009-04-06

Last Posted Date: 2012-10-19

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 400

Registration Number: NCT00876252

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47

Phase 1

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: IC47

First Posted Date: 2009-04-01

Last Posted Date: 2012-10-19

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 32

Registration Number: NCT00873431

Locations: 🇩🇪
Parexel International GmbH, Institute for Clinical Pharmacology, Berlin, Germany

Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: IC43
Drug: Placebo

First Posted Date: 2008-10-23

Last Posted Date: 2012-10-19

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 157

Registration Number: NCT00778388

Locations: 🇩🇪
Dr. Jutta Harten, Münster, Germany
🇦🇹
Univ.-Prof. Dr. Bernd Jilma, Vienna, Austria
🇩🇪
Dr. Daniel Sehrt, Göttingen, Germany

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Phase 3

Completed

Conditions: Japanese Encephalitis

Interventions: Biological: IC51

First Posted Date: 2008-10-21

Last Posted Date: 2016-05-04

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 304

Registration Number: NCT00776230

Locations: 🇩🇪
Berliner Zentrum Reise- und Tropenmedizin, Berlin, Germany
🇩🇪
Universitätsklinikum Rostock, Rostock, Germany
🇦🇹
Zentrum für Reisemedizin, Vienna, Austria

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Phase 3

Completed

Conditions: Japanese Encephalitis

Interventions: Biological: Japanese Encephalitis purified inactivated vaccine (IC51)
Biological: Placebo

First Posted Date: 2008-01-30

Last Posted Date: 2024-03-21

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 2675

Registration Number: NCT00605085

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Phase 3

Completed

Conditions: Japanese Encephalitis

Interventions: Biological: IC51
Biological: JE-VAX

First Posted Date: 2008-01-30

Last Posted Date: 2024-03-21

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 867

Registration Number: NCT00604708

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy